Bahru Habtemariam

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

Robert Q. Le, Liang Li, Weishi Yuan et al. · The Oncologist · 2018 · 859 citations · Full text

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

Thomas M. Herndon, Albert Deisseroth, Edvardas Kaminskas et al. · Clinical Cancer Research · 2013 · 240 citations

Hematological Malignancy, Thrombosis, Translational Medicine +15

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Angelo de Claro, Karen M. McGinn, Virginia E. Kwitkowski et al. · Clinical Cancer Research · 2012 · 207 citations

Lymphoid Neoplasia, Translational Medicine, Hodgkin Lymphoma +12

Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects

Bahru Habtemariam, Verena Karsten, Husain Attarwala et al. · Clinical Pharmacology & Therapeutics · 2020 · 159 citations

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

R. Angelo de Claro, Karen M. McGinn, Nicole Verdun et al. · Clinical Cancer Research · 2015 · 156 citations

Preclinical Therapeutics, Tyrosine Kinase, Pathology +18